| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5178 | Tmq0153 | Novel activator of necrostatin-1 sensitive necroptotic cell death, triggering apoptosis, autophagy and necroptosis crosstalk in chronic myeloid leukemia |
|
| DCC5179 | Tnfalpha-in-4e | Novel potent inhibitor of TNF-α |
|
| DCC5180 | Tnfalpha-in-5783168 | Novel inhibitor of tumor necrosis factor-α (TNF-α) |
|
| DCC5181 | Tnk-6123 | Emivirine analog with improved activity against drug-resistant HIV mutants |
|
| DCC5182 | Tnk-651 | Novel non-nucleoside reverse transcriptase inhibitor of HIV-1 |
|
| DCC5183 | Tnks/usp25-in-c44 | Novel selective inhibitor of TNKS-USP25 interaction, effectively reducing prostate cancer cell proliferation and tumor growth |
|
| DCC5184 | Tnks2-in-5 | Novel highly potent and selective TNKS2 inhibitor with antiproliferative effects in a colorectal cancer cell line (DLD-1) where the Wnt pathway is constitutively activated |
|
| DCC5185 | Tnks-in-1 | Highly potent and selective tankyrase inhibitor |
|
| DCC5186 | Tnks-in-21 | Novel potent and selective tankyrase (TNKS) inhibitor |
|
| DCC5187 | Tnp-2092 | Unique multitargeting drug conjugate with extremely low propensity for development of resistance, targeting RNA polymerase, DNA gyrase, and DNA topoisomerase IV |
|
| DCC5188 | Tol8-agonist-31a | Novel Human Toll-like Receptor 8-Selective Agonist |
|
| DCC5189 | Toldimfos Sodium | Stimulator of metabolism, preventing diseases associated with parturition and peri-partum period, developmental and nutritional disorders in young animals, and bone growth disorders and tetany or paresis caused by calcium, magnesium, and phosphorus metabo |
|
| DCC5190 | Tonantzitlolone | Natural agonist of TPRC1/4/5 channels, also acting as a dual PKCα and PKCθ activator, inducing an insulin resistant phenotype by inhibiting IRS1 and the PI3K/Akt pathway, activating the heat shock factor 1 (HSF1) transcription factor driving glucose depen |
|
| DCC5191 | Top1/tdp1-in-c12 | Novel dual TOP1 and TDP1 inhibitor, inducing both cellular TOP1cc, TDP1cc formation and DNA damage, resulting in cancer cell apoptosis at a sub-micromolar concentration |
|
| DCC5192 | Top1210 | Novel narrow spectrum kinase inhibitor, potently inhibiting P38a, Src, and Syk kinase activities |
|
| DCC5193 | Top-dnj | Novel Selective Inhibitor of Endoplasmic Reticulum α-Glucosidase II, Exhibiting Antiflaviviral Activity |
|
| DCC5194 | Topki-nbd | Novel highly specific fluorescent TOPK inhibitor |
|
| DCC5195 | To-pro3 Iodide | Nucleic acid stain, acting on viable, early apoptotic and necrotic cells differentially, showing specific staining of nuclei without any staining of the cytoplasm |
|
| DCC5196 | Tortuosamine | Natural psychoactive agent |
|
| DCC5197 | Tos-gly-pro-arg-anba-ipa | Chromogenic peptide substrate for the rapid and specific photometric assay of recombinant hirudin (r-hirudin) |
|
| DCC5198 | Tosylaniline | Selective CA IX inhibitor |
|
| DCC5199 | Toxt-in-8 | Novel ToxT inhibitor, reducing Vibrio cholerae virulence in vivo and effectively inhibiting intestinal colonization in the infant mouse |
|
| DCC5200 | Tp-008 | Novel probe for activin receptor-like kinase (ALK4 and ALK5) |
|
| DCC5201 | Tp-040 | Novel inhibitor of O-GlcNAcase (OGA) |
|
| DCC5202 | Tp-238 Hydrochloride | Novel probe for CECR2/BPTF bromodomains |
|
| DCC5203 | Tpe-gal | First-in-class fluorescent drug delivery vesicle that can efficiently load both water-soluble and -insoluble anticancer drugs |
|
| DCC5204 | Tph1-in-23a | Novel Peripheral Selective Tryptophan Hydroxylase 1 (TPH1) Inhibitor (IC 50 : 42nM) for Obesity and Fatty Liver Disease |
|
| DCC5205 | Tpi1609-10 | Inhibitor of tyrosine recombinases and Holliday junction-resolving enzymes; Antibacterial |
|
| DCC5206 | Tpi-1917-49 | Promising amyloid reducing agent by lowering the levels of Aβ. |
|
| DCC5207 | Tpi-2659-17 | Novel Specific Inhibitor of Type I Collagen Production in Fibrosis |
|
